Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00782652 · ClinicalTrials.gov registry record · Phase 2

The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients

A Phase 2 study, sponsored by Mallinckrodt.

Terminated
Registry status
Phase 2
Development phase
3
Enrollment target

NCT00782652: Clinical Trial Phase 2 study, sponsored by Mallinckrodt.

NCT00782652 is a Phase 2 study that was terminated before completion, run by Mallinckrodt. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00782652, a Phase 2 study, was terminated before completion, sponsored by Mallinckrodt.

TERMINATED
Registry status
Phase 2
Development phase
3 participants
Enrollment target

Study Summary

This study is designed to better understand the effects of nitric oxide, a gas for inhalation, on patients with right ventricular infarction.

Interventions

  • DRUG inhaled nitric oxide
  • DRUG nitrogen gas

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2006-03
Est. Completion 2007-02
Phase Phase 2
Mallinckrodt

69 total trials

Why NCT00782652 stopped before completion

NCT00782652 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which inhaled nitric oxide is the first listed.

NCT00782652 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00782652 about?

NCT00782652 is a clinical study titled "The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients". This study is designed to better understand the effects of nitric oxide, a gas for inhalation, on patients with right ventricular infarction.

What is the current status of trial NCT00782652?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2006-03. Estimated completion is 2007-02.

What interventions are being tested in trial NCT00782652?

The interventions under investigation include: inhaled nitric oxide (DRUG), nitrogen gas (DRUG).

Who is sponsoring clinical trial NCT00782652?

This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00782652's enrollment target sits among peer trials

3 2001st of 2000 the lowest of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00782652, the US trial registry maintained by the National Library of Medicine. NCT00782652 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.